Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma cash
Cash and short-term investments held at the end of each period.
Innate Pharma's cash was €6.46M at Jun 30, 2026. For fiscal 2025 it was €28.09M, down 57.7% from the year before. The highest annual figure on record is €202.89M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €28.09M | -57.7% |
| FY2024 | Dec 31, 2024 | €66.40M | -6.0% |
| FY2023 | Dec 31, 2023 | €70.61M | -16.2% |
| FY2022 | Dec 31, 2022 | €84.23M | -18.8% |
| FY2021 | Dec 31, 2021 | €103.76M | -24.2% |
| FY2020 | Dec 31, 2020 | €136.79M | -32.6% |
| FY2019 | Dec 31, 2019 | €202.89M | +33.2% |
| FY2018 | Dec 31, 2018 | €152.31M | +53.3% |
| FY2017 | Dec 31, 2017 | €99.37M | -43.5% |
| FY2016 | Dec 31, 2016 | €175.91M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €6.46M | -90.8% |
| Q4 FY2025 | Dec 31, 2025 | €28.09M | -60.2% |
| Q2 FY2025 | Jun 30, 2025 | €53.70M | -24.8% |
| Q4 FY2024 | Dec 31, 2024 | €66.40M | -21.2% |
| Q2 FY2024 | Jun 30, 2024 | €69.99M | -32.0% |
| Q4 FY2023 | Dec 31, 2023 | €70.61M | -32.0% |
| Q2 FY2023 | Jun 30, 2023 | €71.41M | -31.3% |
| Q4 FY2022 | Dec 31, 2022 | €84.23M | -38.4% |
| Q2 FY2022 | Jun 30, 2022 | €102.95M | -21.7% |
| Q4 FY2021 | Dec 31, 2021 | €103.76M | -48.9% |
| Q2 FY2021 | Jun 30, 2021 | €103.98M | -31.7% |
| Q4 FY2020 | Dec 31, 2020 | €136.79M | +37.7% |
| Q2 FY2020 | Jun 30, 2020 | €131.54M | -25.2% |
| Q4 FY2019 | Dec 31, 2019 | €202.89M | – |
| Q4 FY2018 | Dec 31, 2018 | €152.31M | – |
| Q4 FY2017 | Dec 31, 2017 | €99.37M | – |
| Q4 FY2016 | Dec 31, 2016 | €175.91M | – |
See a number that looks wrong?